14 November 2018
Source: Macular Society
Researchers from Taiwan have shown that people with type 2 diabetes who took a common diabetes medication, had a significantly lower rate of age-related macular degeneration (AMD).
The study suggests that the anti-inflammatory and anti-oxidative effects of the drug metformin can protect against AMD, while it controls diabetes. The research was presented at AAO 2018, the 122nd Annual Meeting of the American Academy of Ophthalmology.
Inflammation and oxidative stress have long been known to play a key role in the development of both diabetes and AMD. Because metformin suppresses inflammation and oxidative stress, researchers in Taiwan theorised that perhaps the diabetes drug may also protect against AMD, one of the leading causes of blindness in Americans over age 50, affecting about 2.1 million people nationwide.
Read the full story on the Macular Society website